Open access
Aug 2026
Development of isonicotinoyl-azole hybrids as potential InhA inhibitors for anti-tubercular activity.
The development of innovative treatment medicines that can overcome drug resistance and intracellular persistence is necessary since tuberculosis (TB) continues to be a significant worldwide health burden. In this work, series of hybrid compounds containing azole moieties, imine/semicarbazide linkers, and isonicotinoyl...
Wagdy M. Eldehna, Zainab M. Elsayed, M. Korycka-Machała et al.
· RSC Medicinal Chemistry · 0 citations